Research programme: neurological disorder therapeutics - Promius Pharma
Latest Information Update: 28 Feb 2023
At a glance
- Originator Promius Pharma
- Class Antiepileptic drugs; Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Parkinson's disease
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Epilepsy in USA
- 28 Feb 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 01 Jan 2019 Preclinical trials in Epilepsy in USA before January 2019 (Promius Pharma pipeline, January 2019)